DK4126932T3 - Anti-bk-virusantistofmolekyler - Google Patents

Anti-bk-virusantistofmolekyler Download PDF

Info

Publication number
DK4126932T3
DK4126932T3 DK21730952.5T DK21730952T DK4126932T3 DK 4126932 T3 DK4126932 T3 DK 4126932T3 DK 21730952 T DK21730952 T DK 21730952T DK 4126932 T3 DK4126932 T3 DK 4126932T3
Authority
DK
Denmark
Prior art keywords
virus antibodies
antibodies molecules
molecules
virus
antibodies
Prior art date
Application number
DK21730952.5T
Other languages
English (en)
Other versions
DK4126932T5 (da
Inventor
Marcel Weber
Simone Schmitt
Christoph Esslinger
Thomas Schachtner
Uyen Huynh-Do
Maurizio Provenzano
Original Assignee
Memo Therapeutics Ag
Univ Bern
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memo Therapeutics Ag, Univ Bern, Univ Zuerich filed Critical Memo Therapeutics Ag
Publication of DK4126932T3 publication Critical patent/DK4126932T3/da
Application granted granted Critical
Publication of DK4126932T5 publication Critical patent/DK4126932T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
DK21730952.5T 2020-06-09 2021-06-09 Anti-bk-virusantistofmolekyler DK4126932T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20179044 2020-06-09
EP20179041 2020-06-09
PCT/EP2021/065462 WO2021250097A1 (en) 2020-06-09 2021-06-09 Anti-bk virus antibody molecules

Publications (2)

Publication Number Publication Date
DK4126932T3 true DK4126932T3 (da) 2024-01-22
DK4126932T5 DK4126932T5 (da) 2024-07-22

Family

ID=76325565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21730952.5T DK4126932T5 (da) 2020-06-09 2021-06-09 Anti-bk-virusantistofmolekyler

Country Status (26)

Country Link
US (2) US11919943B2 (da)
EP (2) EP4126932B1 (da)
JP (1) JP7840274B2 (da)
KR (1) KR20230035578A (da)
CN (1) CN115776988B (da)
AU (1) AU2021288986A1 (da)
BR (1) BR112022024288A2 (da)
CA (1) CA3181750A1 (da)
CL (1) CL2022003491A1 (da)
CO (1) CO2023000070A2 (da)
DK (1) DK4126932T5 (da)
ES (1) ES2971001T3 (da)
FI (1) FI4126932T3 (da)
HR (1) HRP20231739T1 (da)
HU (1) HUE065440T2 (da)
IL (1) IL298803A (da)
LT (1) LT4126932T (da)
MX (1) MX2022015071A (da)
PE (1) PE20231444A1 (da)
PL (1) PL4126932T3 (da)
PT (1) PT4126932T (da)
RS (1) RS65172B1 (da)
SI (1) SI4126932T1 (da)
SM (1) SMT202400015T1 (da)
WO (1) WO2021250097A1 (da)
ZA (1) ZA202212136B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
HUE065440T2 (hu) 2020-06-09 2024-05-28 Memo Therapeutics Ag Anti-BK-vírus antitestmolekulák
WO2023175171A1 (en) * 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
WO2025252935A1 (en) 2024-06-07 2025-12-11 Universite De Strasbourg Bkv neutralizing antibodies
EP4659811A1 (en) * 2024-06-07 2025-12-10 Université de Strasbourg Bk virus neutralizing antibodies
WO2025252939A1 (en) * 2024-06-07 2025-12-11 Universite De Strasbourg Bk virus neutralizing antibodies
EP4659810A1 (en) 2024-06-07 2025-12-10 Université de Strasbourg Bkv neutralizing antibodies
CN119320446B (zh) * 2024-12-02 2026-01-20 上海云泽生物科技有限公司 一种抗bkv抗体及其应用
CN120623324B (zh) * 2025-08-13 2025-10-31 北京溯本源和生物科技有限公司 一种用于bk病毒vp1蛋白检测的单克隆抗体3c7及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936980B (zh) * 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
HUE065440T2 (hu) 2020-06-09 2024-05-28 Memo Therapeutics Ag Anti-BK-vírus antitestmolekulák

Also Published As

Publication number Publication date
US20240132575A1 (en) 2024-04-25
EP4327883A3 (en) 2024-05-22
MX2022015071A (es) 2023-02-27
HUE065440T2 (hu) 2024-05-28
EP4126932B1 (en) 2023-11-15
CA3181750A1 (en) 2021-12-16
IL298803A (en) 2023-02-01
US20230192816A1 (en) 2023-06-22
US20240228590A9 (en) 2024-07-11
SI4126932T1 (sl) 2024-03-29
CL2022003491A1 (es) 2023-08-11
LT4126932T (lt) 2024-02-12
AU2021288986A1 (en) 2022-12-15
KR20230035578A (ko) 2023-03-14
WO2021250097A1 (en) 2021-12-16
SMT202400015T1 (it) 2024-03-13
BR112022024288A2 (pt) 2023-01-31
PT4126932T (pt) 2024-01-18
DK4126932T5 (da) 2024-07-22
PL4126932T3 (pl) 2024-04-22
CN115776988A (zh) 2023-03-10
FI4126932T3 (fi) 2024-01-18
HRP20231739T1 (hr) 2024-03-15
JP7840274B2 (ja) 2026-04-03
PE20231444A1 (es) 2023-09-14
RS65172B1 (sr) 2024-03-29
ES2971001T3 (es) 2024-06-03
JP2023528828A (ja) 2023-07-06
CN115776988B (zh) 2025-10-17
US11919943B2 (en) 2024-03-05
EP4126932A1 (en) 2023-02-08
EP4327883A2 (en) 2024-02-28
CO2023000070A2 (es) 2023-02-16
ZA202212136B (en) 2024-02-28

Similar Documents

Publication Publication Date Title
SI4126932T1 (sl) Molekule protiteles virusa anti-bk
IL280004A (en) Antibody molecules that bind pd-l1 and cd137
EP4225364A4 (en) Prefusion-stabilized hmpv f proteins
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
PL3645570T3 (pl) Cząsteczki wiążące antygen VISTA
DK4214240T3 (da) Anti-ccr8-antistoffer
EP4081547A4 (en) Novel anti-fgfr2b antibodies
IL292625A (en) Viruses with modified capsid proteins
IL290371A (en) Novel antigen binding molecule formats
IL311043A (en) Anti-il-11rα antibodies
IL287423A (en) Antibodies and methods for treatment of influenza a infection
EP4277927A4 (en) NEW ANTI-GREMLIN-1 ANTIBODIES
EP3990428A4 (en) Novel molecules
EP4463485A4 (en) Tetrahedral antibodies
EP4081539A4 (en) Novel anti-fgfr2b antibodies
IL310245A (en) Anti-hla-g antibodies
EP4414388A4 (en) NEW ANTI-L1CAM ANTIBODY
EP3452504A4 (en) MONOCLONAL DNA ANTIBODIES TARGETING INFLUENZA VIRUS
EP4522758A4 (en) ABCA4 TRANS-SPLICING MOLECULES
EP4532558A4 (en) ANTI-ROR1 ANTIBODIES
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
EP4339213A4 (en) Antigen-binding molecule
IL292799A (en) Anti-siglec-9 antibody molecules
EP3986389A4 (en) CONJUGATED CANNABINOIDS MOLECULES
IL312470A (en) Novel proteins